ResearcherNew York UniversityActive in the last 2 years

Arturo Orlacchio

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6044-4258; OpenAlex author ID A5052556733. Sources: OpenAlex.

Their work

Papers: 3 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 3

Continuous Regression of Metastatic Pancreatic Adenocarcinoma after Suspending Chemotherapy: A Case Report. First author DOI 10.1159/000549360 ↗
Epigenetic therapeutic strategies in pancreatic cancer. Co-author DOI 10.1016/bs.ircmb.2023.10.002 ↗
The Role of Toll-like Receptors (TLRs) Mediated Inflammation in Pancreatic Cancer Pathophysiology. Co-author DOI 10.3390/ijms222312743 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Leyla Bayat · 1 shared paper, 2025 · strength 0.37
- Paper Continuous Regression of Metastatic Pancreatic Adenocarcinoma after Suspending Chemotherapy: A Case Report. DOI 10.1159/000549360 ↗
Jennifer Wu · 1 shared paper, 2025 · strength 0.37
- Paper Continuous Regression of Metastatic Pancreatic Adenocarcinoma after Suspending Chemotherapy: A Case Report. DOI 10.1159/000549360 ↗
Tamas A. Gonda · 1 shared paper, 2024 · strength 0.36
- Paper Epigenetic therapeutic strategies in pancreatic cancer. DOI 10.1016/bs.ircmb.2023.10.002 ↗
Pellegrino Mazzone · 1 shared paper, 2021 · strength 0.28
- Paper The Role of Toll-like Receptors (TLRs) Mediated Inflammation in Pancreatic Cancer Pathophysiology. DOI 10.3390/ijms222312743 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.